Hollander A P, Corke K P, Freemont A J, Lewis C E
University of Bristol, Avon Orthopaedic Centre, Southmead Hospital, UK.
Arthritis Rheum. 2001 Jul;44(7):1540-4. doi: 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7.
To determine if the rheumatoid synovium is a suitable target for hypoxia-regulated gene therapy.
Sequential sections of wax-embedded synovial membrane samples were obtained from 10 patients with rheumatoid arthritis (RA), 10 with primary osteoarthritis (OA), and from 6 healthy controls. Membrane sections from each patient were immunostained for hypoxia-inducible factor 1alpha (HIF-1alpha) and CD68 (a pan-macrophage marker).
HIF-1alpha was expressed abundantly by macrophages in most rheumatoid synovia, predominantly close to the intimal layer but also in the subintimal zone. There was markedly lower expression of HIF-1alpha in OA synovia, and it was absent from all of the healthy synovia.
These observations indicate that macrophages transduced with a therapeutic gene under the control of a hypoxia-inducible promoter could be administered to RA patients systemically. Migration of these cells to synovial tissue would result in the transgene being switched on in diseased joints but not in healthy tissues.
确定类风湿滑膜是否是缺氧调节基因治疗的合适靶点。
从10例类风湿关节炎(RA)患者、10例原发性骨关节炎(OA)患者和6例健康对照者中获取石蜡包埋滑膜组织样本的连续切片。对每位患者的膜切片进行缺氧诱导因子1α(HIF-1α)和CD68(一种全巨噬细胞标志物)的免疫染色。
在大多数类风湿滑膜中,巨噬细胞大量表达HIF-1α,主要靠近内膜层,但也在内膜下层区域。OA滑膜中HIF-1α的表达明显较低,所有健康滑膜中均未检测到。
这些观察结果表明,在缺氧诱导启动子控制下用治疗性基因转导的巨噬细胞可以全身性地给予RA患者。这些细胞迁移到滑膜组织将导致转基因在患病关节中开启,但在健康组织中不开启。